AVA6103
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvar Adenocarcinoma
Conditions
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung
Trial Timeline
Mar 1, 2026 → Jun 1, 2030
NCT ID
NCT07454642About AVA6103
AVA6103 is a phase 1 stage product being developed by Avacta Group for Vulvar Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07454642. Target conditions include Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07454642 | Phase 1 | Recruiting |
Competing Products
7 competing products in Vulvar Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 52 |
| Estradiol | Sun Pharmaceutical | Phase 3 | 77 |
| Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Cisplatin + Pembrolizumab | Merck | Phase 2 | 52 |
| Cardunolizumab | Innovent Biologics | Phase 2 | 51 |
| AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin | Akeso | Phase 2 | 51 |
| VGX-3100 + Imiquimod 5% Cream | Inovio Pharmaceuticals | Phase 2 | 44 |